AbbVie Inc (ABBV)

64.72
0.18 0.28
NYSE : Health Care
Prev Close 64.90
Open 64.79
Day Low/High 63.93 / 65.06
52 Wk Low/High 45.45 / 71.51
Volume 3.94M
Avg Volume 9.14M
Exchange NYSE
Shares Outstanding 1.62B
Market Cap 104.24B
EPS 3.20
P/E Ratio 19.35
Div & Yield 2.28 (3.50%)

Latest News

Hep C Business Slow-Down Could Hamper Bristol-Myers' Future

Hep C Business Slow-Down Could Hamper Bristol-Myers' Future

The company's hepatitis C drug division is expected to see losses in the second half of the year.

What to Look for When AbbVie (ABBV) Reports Q2 Results

What to Look for When AbbVie (ABBV) Reports Q2 Results

AbbVie (ABBV) will report 2016 second quarter earnings on Friday before the market open.

Top 10 Dividend Aristocrats to Buy at a Discount Now

Top 10 Dividend Aristocrats to Buy at a Discount Now

These 10 dividend aristocrat stocks offer an average high yield of 3% and have increased dividends for 46 consecutive years on average.

Experimental Tau Protein Drug Tangled Up in Late-Stage Alzheimer's Study Failure

Experimental Tau Protein Drug Tangled Up in Late-Stage Alzheimer's Study Failure

A TauRx Therapeutics drug designed to dissolve tangles of a protein called tau in the brain failed to slow cognitive and functional declines of Alzheimer's patients compared with a control.

Buy Gilead Sciences While It's Wallowing

Buy Gilead Sciences While It's Wallowing

It's too cheap for a biotech giant with years of patent protection for key products and great cash flow.

AbbVie Receives U.S. FDA Approval Of Once-Daily VIEKIRA XR™ (dasabuvir, Ombitasvir, Paritaprevir And Ritonavir) For The Treatment Of Genotype 1 Chronic Hepatitis C

AbbVie Receives U.S. FDA Approval Of Once-Daily VIEKIRA XR™ (dasabuvir, Ombitasvir, Paritaprevir And Ritonavir) For The Treatment Of Genotype 1 Chronic Hepatitis C

- New extended-release formulation is the first all-oral, co-formulated treatment containing the three direct-acting antiviral components of VIEKIRA PAK® for adult patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection

AbbVie And Bristol-Myers Squibb Announce Oncology Clinical Collaboration To Evaluate The Combination Of Rova-T Plus Opdivo And Opdivo + Yervoy Regimen

AbbVie And Bristol-Myers Squibb Announce Oncology Clinical Collaboration To Evaluate The Combination Of Rova-T Plus Opdivo And Opdivo + Yervoy Regimen

- Collaboration will explore the safety and potential enhanced efficacy of combining checkpoint inhibitors with a cancer stem cell-targeting antibody drug conjugate in SCLC

AbbVie And Bristol-Myers Squibb Announce Oncology Clinical Collaboration To Evaluate The Combination Of Rova-T Plus Opdivo And Opdivo + Yervoy Regimen

AbbVie And Bristol-Myers Squibb Announce Oncology Clinical Collaboration To Evaluate The Combination Of Rova-T Plus Opdivo And Opdivo + Yervoy Regimen

AbbVie (NYSE:ABBV) and Bristol-Myers Squibb Company (NYSE:BMY) today announced a clinical trial collaboration to evaluate the safety, tolerability and efficacy of AbbVie's investigational biomarker-specific antibody...

CHMP Grants Positive Opinion For Shorter Treatment Duration With AbbVie's VIEKIRAX® (ombitasvir/paritaprevir/ritonavir Tablets) For Patients With Genotype 4 Chronic Hepatitis C With Compensated Cirrhosis (Child-Pugh A)

CHMP Grants Positive Opinion For Shorter Treatment Duration With AbbVie's VIEKIRAX® (ombitasvir/paritaprevir/ritonavir Tablets) For Patients With Genotype 4 Chronic Hepatitis C With Compensated Cirrhosis (Child-Pugh A)

- The CHMP opinion represents a positive advance toward approval of the 12-week regimen of VIEKIRAX with ribavirin for genotype 4 (GT4) chronic hepatitis C virus (HCV) infected adult patients with or without compensated cirrhosis

Do the Math! Stocks Are Poised for a Fall

Do the Math! Stocks Are Poised for a Fall

Optimism is warranted over the long haul, but investors probably face a short-term headache. Here are the crucial numbers and events to watch in the week ahead.

Week Ahead: Fed's July Meeting Overshadows Another Busy Earnings Week

Week Ahead: Fed's July Meeting Overshadows Another Busy Earnings Week

The Federal Reserve will steal focus from another onslaught of earnings in the coming week as investors remain wary over the central bank's rate-hike timetable.

3 Stocks Driving The Drugs Industry Higher

3 Stocks Driving The Drugs Industry Higher

TheStreet highlights 3 stocks pushing the drugs industry higher today.

Why Nasdaq-Traded Marijuana Stocks Remain Undervalued

Why Nasdaq-Traded Marijuana Stocks Remain Undervalued

Nasdaq-traded marijuana stocks are undervalued as investors remain skittish and the use of drugs produced by these biopharmaceutical companies have not been widely adopted.

3 Stocks Pulling The Health Care Sector Downward

3 Stocks Pulling The Health Care Sector Downward

TheStreet highlights 3 stocks pushing the health care sector lower today.

Could the Dow Jump Up Another 400 Points by Year-End?

Could the Dow Jump Up Another 400 Points by Year-End?

Concerns that the market is overvalued continue to arise as the S&P 500 has increased by 7.6% during the past two weeks. But there may still be room for growth.

AbbVie Payout Reminder; Buy Today

Don't miss strong performer ABBV's $0.57 dividend.

Shire’s Shares Rise on FDA Approval of Dry Eye Med

Shire’s Shares Rise on FDA Approval of Dry Eye Med

Jefferies estimates Xiidra could yield revenue of $1.5 billion within five years of its launch.

AbbVie Presents Initial Data From Pivotal Phase-3 Trial Evaluating The Efficacy And Safety Of HUMIRA® (adalimumab) For Moderate To Severe Fingernail Psoriasis In Adult Patients At Psoriasis 2016 Congress

AbbVie Presents Initial Data From Pivotal Phase-3 Trial Evaluating The Efficacy And Safety Of HUMIRA® (adalimumab) For Moderate To Severe Fingernail Psoriasis In Adult Patients At Psoriasis 2016 Congress

- Data from Phase 3 randomized, placebo controlled trial demonstrates that 46.6 percent of adult patients with moderate to severe psoriasis treated with HUMIRA® achieved at least a 75 percent improvement in their moderate to severe fingernail psoriasis

AbbVie Is Poised to Move Even Higher

AbbVie Is Poised to Move Even Higher

With solid footing developing underneath and room to run on the upside, AbbVie is setting up well for a fresh rally.

Take Stock of Your High-Dividend Stocks

Valuations are stretched in certain names and industries, so some profit-taking appears in order.

Take Stock of Your High-Dividend Stocks

Valuations are stretched in certain names and industries, so some profit-taking appears in order.

Biogen And AbbVie's Once-Monthly ZINBRYTA™ (Daclizumab) Approved In European Union For Treatment Of Multiple Sclerosis

Biogen And AbbVie's Once-Monthly ZINBRYTA™ (Daclizumab) Approved In European Union For Treatment Of Multiple Sclerosis

The European Commission (EC) has granted marketing authorization for ZINBRYTA™ (daclizumab) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), Biogen (NASDAQ: BIIB) and AbbVie...

Picking Up More Orasure

A terminated co-promotion sent shares lower, so we'll use this as a buying opportunity.

AbbVie's HUMIRA® (adalimumab) Receives U.S. Food And Drug Administration Approval To Treat Adults With Non-Infectious Intermediate, Posterior And Panuveitis

AbbVie's HUMIRA® (adalimumab) Receives U.S. Food And Drug Administration Approval To Treat Adults With Non-Infectious Intermediate, Posterior And Panuveitis

- Non-infectious uveitis is an immune-mediated disease that can flare and impair vision

Company Updates and Dividend Reminder

It's the last day of the quarter; earnings season is around the corner.

16 Biopharma Companies Besides Medivation That Are Attractive Targets

16 Biopharma Companies Besides Medivation That Are Attractive Targets

Besides Sanofi, Biogen is the next most likely to complete a sizable transaction in the next 12 months, according to Credit Suisse analysts.